Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 12/20 | 0.66 |
| ▸ | HTT | P42858 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15636098 | 0.90 | DHODH (0.54) | DHODHHTTMEN1KMT2APKM | |
| SCHEMBL20294285 | 0.88 | DHODH (0.67) | DHODHHTTMEN1KMT2APKM | |
| SCHEMBL17110886 | 0.85 | DHODH (0.64) | DHODHHTTMEN1KMT2APKM | |
| SCHEMBL1487202 | 0.83 | DHODH (0.78) | DHODHHTTMEN1KMT2APKM | |
| SCHEMBL15635970 | 0.81 | MAPT (0.49) | DHODHHTTMEN1KMT2APKM | |
| SCHEMBL729168 | 0.80 | DHODH (1.00) | DHODHHTTMEN1KMT2APKM | |
| SCHEMBL17110914 | 0.78 | MAPT (0.48) | DHODHHTTMEN1KMT2AHDAC6 | |
| SCHEMBL15635046 | 0.78 | MAPT (0.48) | DHODHHTTMEN1KMT2AMAPK1 | |
| SCHEMBL17112675 | 0.78 | MAPT (0.48) | DHODHHTTMEN1KMT2AMAPK1 | |
| SCHEMBL17112625 | 0.78 | MAPT (0.48) | DHODHHTTMEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903965-B1 | N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | ORION CORP (FI) | 2017-03-01 | — | — | EP | disclosed |
| US-9533952-B2 | N-prop-2-ynyl carboxamide derivatives and their use as TRPA1 antagonists | ORION CORPORATION (FI) | 2017-01-03 | — | — | US | disclosed |
| US-20150376130-A1 | N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | Orlon Corporation (FI) | 2015-12-31 | — | — | US | disclosed |
| WO-2015144976-A1 | TRPA1 MODULATORS | ORION CORPORATION (FI) | 2015-10-01 | — | — | WO | disclosed |
| EP-2903965-A1 | N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | Orion Corporation (FI) | 2015-08-12 | — | — | EP | disclosed |
| WO-2014053694-A1 | N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | ORION CORPORATION (FI) | 2014-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376130-A1 | N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | TRPA1, TRPV1, TRPV2 | DHODH 4334/4885HTT 987/4885MEN1 3912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.